OTTAWA, March 9, 2017 /CNW/ - Health Canada recognizes that access to clinical information can help health researchers andpractitioners, improve patient safety and health outcomes for Canadians. To that end, Health Canada is proposing to proactively make certain clinical information from drug submissions and medical device applications publicly available following the completion
This approach would support Canada's Open Government initiative to create greater transparency and accountability, increase citizen engagement, and drive innovation and economic opportunities through open data, open information, and open dialogue.
Improving access to this information would also make Health Canada more accountable for its decisions and enable closer public scrutiny of researchers' and product sponsors' findings. In addition, Health Canada's approach would be better aligned with the policies of forward-thinking international regulators, including the European Medicines Agency and the US Food and Drugs Administration.
Canadians have 75 days to provide their feedback on the white paper.
Health Canada is also publishing the final guidance document on Disclosure of Confidential Business Information under the Food and Drugs Act.
This guidance applies to Health Canada's existing authority to disclose confidential business information regarding therapeutic products. It would continue to apply to other confidential business information that would not become publicly available as a result of the proposal in the white paper on Public Release of Clinical Information in Drug Submissions and Medical Device Applications.
This guidance document is part of Health Canada's existing Regulatory Transparency and Openness Framework. Through the Framework, Health Canada has committed to providing Canadians greater access to credible, timely and useful information to allow them to make well-informed decisions concerning their health and that of their families.
Draft Guidance Document Disclosure of Confidential Business Information under the Food and Drugs Act
SOURCE Health Canada
Subscribe to our Free Newsletters!
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All